| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 191.5 | 177.6 | 158.3 |
| Other income | 7.7 | 2.2 | 9.0 |
| Total income | 199.1 | 179.9 | 167.3 |
| Profit before exceptional items & tax | 32.8 | 18.8 | 10.4 |
| Exceptional items | 0.2 | 5.2 | 0.0 |
| Profit before tax | 32.6 | 13.7 | 10.4 |
| Net profit | 24.7 | 16.8 | 8.8 |
| Operating margin | 16.4% | 7.6% | 6.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +180.70% |
|---|---|
| Net profit, quarter on quarter | +47.00% |
| Revenue, year on year | +21.00% |
| Operating profit, year on year | +1692.90% |
| Operating profit, quarter on quarter | +51.20% |
BSE results filing, NSE: INDSWFTLAB. Figures extracted from the filing.
Ind-Swift Laboratories Ltd: key numbers
- Share price
- ₹404.35
- Market cap
- ₹3,516 Cr
- Revenue (annual)
- ₹641.3 Cr
- Net profit (annual)
- ₹41.42 Cr
- P/E (TTM)
- 61.3×Sector 50.4×
- Promoter holding
- 42.93%-0.06% QoQ
- FII holding
- 10.70%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ind-Swift Laboratories Ltd
All →Ind-Swift Laboratories Other Announcement
Ind-Swift Laboratories Ltd has filed its quarterly shareholding pattern as mandated by Regulation 31(1)(c) of the SEBI Listing Regulations.
Ind-Swift Laboratories Capital Structure Change
Promoter entity Essix Biosciences Limited acquired 70,00,000 fully convertible warrants of Ind-Swift Laboratories via a preferential allotment.
Ind-Swift Laboratories Capital Structure Change
Ind-Swift Laboratories allotted 70 lakh fully convertible warrants at Rs. 196 each, totaling Rs. 137.2 Crore. This preferential issue will augment capital upon warrant conversion.
- Value
- ₹137.2 Cr
Ind-Swift Laboratories Capital Structure Change
Ind-Swift Laboratories Limited allotted 70,00,000 fully convertible warrants to Essix Biosciences Limited on a preferential basis. The company received Rs. 34.30 Crore as upfront payment.
- Value
- ₹34.30 Cr
Ind-Swift Laboratories Annual Report
Ind-Swift Laboratories has submitted its Annual Report for the financial year 2025-26. This filing provides the company's detailed financial performance and operational updates.
Ind-Swift Laboratories Annual General Meeting
Ind-Swift Laboratories Ltd will hold its 31st Annual General Meeting on September 30, 2026, via video conference. The agenda includes financial adoption and director appointments.